Review Papers Claim by Claim

Visual summary (top → bottom)

Concise evidence-based critique

1. Structures & data quality: The authors solved three FP–Gq cryo-EM structures to 2.67–3.14 Å and deposited coordinates and maps (PDB: 8IUK/8IUL/8IUM; EMDB:EMD-35724/35725/35726), enabling direct inspection and independent modeling (paper + data availability) FP structures and depositions.
2. Main mechanistic claims (supported):
   • Ligand pose: L-shaped PGF2α binding with α-chain salt bridge to R2917.40 and F-ring contacts to S331.39/T2947.43 — validated by density and loss-of-function mutagenesis (ΔpEC50) Ligand-binding details & mutagenesis.
   • Activation without canonical PIF/DRY motifs: FP lacks canonical PIF triad and DRY → activation instead uses an LLW triad (L1233.40, L2135.49, W2626.48) and ERC motif rearrangement; mutagenesis of LLW residues reduces activity Activation motif replacement (LLW).
   • Gq coupling mode: unusual extensive contacts with TM1/ICL1/TM2 plus ICL2/H8 interactions; ICL1/TM1 mutations (e.g., S62A) abolish IP1 signaling — indicates a distinct Gq docking footprint Gq interface unusual TM1/ICL1/TM2 interactions.
3. Strengths:
   • High-resolution maps (≤2.78 Å for two complexes) with clear ligand density; complementary mutagenesis + IP-One assays tie structure to function.
   • Data, coordinates, and source data available — good transparency and reproducibility potential.
4. Limitations & potential biases (critical):
   • Stabilization artifacts: BRIL N-terminal fusion, scFv16 and Nb35, NanoBiT tethering and an engineered Gαq chimera were used to stabilize complexes — these strategies are standard but can bias receptor/G-protein orientation and H8/TM7 positions; authors acknowledge this in methods/supplementary Construct engineering and caveats.
   • Non-native expression system: Hi5 insect cells and truncated/engineered constructs may not reproduce native post-translational modifications or membrane lipid environment (cholesterol/rafts), which can alter receptor dynamics and G protein specificity (important for lipid receptors).
   • Static snapshots: cryo-EM gives conformational snapshots; dynamic features (microsecond–millisecond exchanges) and ligand-induced kinetics (biased signaling) need orthogonal methods (smFRET, MD, cellular biased signaling panels) to fully validate functional mechanisms — this is general for structural studies (see single-molecule literature for GPCR dynamics) Ligand geometry affects FP pharmacology.
   • Limited in-cell, organismal validation: IP-One assays and surface-expression flow cytometry in AD293 cells are good, but no in vivo functional experiments or patient-derived tissues are shown here; functional consequences (e.g., tissue-selectivity, side-effect mechanisms) remain to be confirmed.
5. Interpretation robustness & alternate explanations:
   • The LLW triad model is well-supported by density and mutagenesis; however, because PIF and DRY motifs are sequence-variant across GPCR subfamilies, alternative long-range allosteric networks (e.g., H8/TM7 repositioning due to stabilization constructs) could contribute to the observed activation pattern — testing in absence of Nb35/scFv16 or with wild-type Gαq would increase confidence.
   • Authors attribute selectivity of LTPA/TFPA partly to extra H-bonds (S118, N84) — these are mechanistically plausible and supported by mutagenesis, but binding/selectivity across the prostanoid receptor panel (EP1–EP4, TP, IP) would further quantify off-target risks and therapeutic windows (some clinical data indicate EP3 cross-reactivity for TFPA) Selectivity determinants LTPA/TFPA.
6. Blindspots & missing experiments I would prioritize:
   1. Repeat key structures with minimal stabilizing partners (remove BRIL/Nb35/scFv16 or use native Gαq) to confirm TM7/H8 and Gαα5 orientations are not tethering artifacts.
   2. Perform MD simulations (apo vs ligand-bound FP in a realistic membrane including cholesterol) to test LLW triad stability and dynamic coupling to cytoplasmic opening; publish trajectories and free-energy differences to enable external re-analysis (open-data).
   3. Conduct comprehensive signaling-biased profiling (Gq, Gi, G12/13, arrestin, Rho) in mammalian cells with native post-translational environment across WT and key mutants (LLW, R291, S118, N84) to quantify functional selectivity and link structure to biased signaling.
   4. Measure ligand affinities (radioligand or SPR in lipid nanodiscs) and on/off rates to complement IP-One potency (pEC50) and separate efficacy vs binding effects.
7. How robust are the paper's conclusions?

   Moderately high confidence that the reported ligand poses and local interactions are correct (good density, mutagenesis corroboration). Moderate confidence that the LLW triad and ER C-based activation represent the physiological activation pathway — good supporting mutagenesis but still potentially influenced by stabilizing agents; lower confidence that the precise Gq docking geometry is identical in native cells without the engineered chimera/tethers. Disconfirming evidence would include structures without stabilizers showing different TM1/TM6/TM7/H8 arrangements or functional assays showing mutants have different effects in primary cells.

8. Practical implications for drug design:
   • Structures provide concrete templates to design ω-chain substitutions that form FP-specific H-bonds (e.g., exploit S118 and N84 region) to improve selectivity and reduce EP/TP off-targets.
   • Awareness of LLW triad suggests small molecules or bitopic ligands that stabilize this local hydrophobic core may act as allosteric modulators or biased agonists; in silico alchemical scans around these residues are a logical next step.

Concrete reproducibility & follow-up checklist

• Obtain deposited maps/models (PDB IDs 8IUK/8IUL/8IUM; EMDB: EMD-35724/35725/35726) and independently validate ligand poses and real-space correlations (RSCC) per ligand atom.
• Reproduce IP-One assays with WT Gαq (non-chimera) in HEK-derived cells and primary cells expressing endogenous FP to check phenotype consistency.
• Run MD in membrane with physiological lipid composition (cholesterol, sphingolipids) to test LLW and TM1–Gα contacts stability; publish trajectories for community validation (addresses known bias sources like membrane composition effects noted in GPCR literature).

Minimal list of supporting citations (paper + methods references)

• Main study and data deposit (structures + assays): Wu et al., Nature Communications 2023 (FP structures)
• AlphaFold2 used as starting model: AlphaFold2 protein structure predictions
• Deep postprocessing: DeepEMhancer for map postprocessing used in paper: DeepEMhancer map postprocessing

Final judgments (concise)

• Evidence strength for ligand poses & key receptor–ligand interactions: strong (good density + mutagenesis).
• Evidence strength for novel activation motif (LLW) and ER C rearrangement: moderate-to-strong (structural + mutagenesis) but requires orthogonal confirmation in minimal-stabilizer contexts.
• Evidence strength for unusual TM1/ICL1/TM2 Gq contacts: moderate (clear in this dataset, but engineered G protein and tethering may bias packing).

Next-step experiments I would run (short actionable list)

1. Cryo-EM FP–Gq structure with native (non-chimeric) Gαq and without NanoBiT/Nb35/scFv16 to check for positional shifts in Gα α5 helix, TM7/H8 and TM1 contacts.
2. MD simulations in mixed-lipid bilayers (POPC:chol:SM) and free-energy perturbation (FEP) alchemical scans for ligand ω-chain substitutions to quantify selectivity contribution of S118 and N84 interactions.
3. Signaling-bias panel across Gq/Gi/G12/13/arrestin in primary ocular cells and AD293 to quantify whether LTPA/TFPA offer therapeutic bias reducing side effects.